RhumbLine Advisers’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-7,117
Closed -$376K 3055
2020
Q3
$376K Sell
7,117
-1,095
-13% -$67.6K ﹤0.01% 2421
2020
Q2
$503K Buy
8,212
+578
+8% +$33.4K ﹤0.01% 2343
2020
Q1
$432K Hold
7,634
﹤0.01% 2231
2019
Q4
$435K Buy
7,634
+59
+0.8% +$3.13K ﹤0.01% 2424
2019
Q3
$405K Sell
7,575
-75
-1% -$4.37K ﹤0.01% 2423
2019
Q2
$457K Buy
7,650
+344
+5% +$21.6K ﹤0.01% 2395
2019
Q1
$455K Sell
7,306
-224
-3% -$14.8K ﹤0.01% 2365
2018
Q4
$456K Buy
7,530
+2,492
+49% +$149K ﹤0.01% 2337
2018
Q3
$295K Sell
5,038
-300
-6% -$15.3K ﹤0.01% 2519
2018
Q2
$239K Buy
5,338
+355
+7% +$15.3K ﹤0.01% 2652
2018
Q1
$221K Sell
4,983
-175
-3% -$7.35K ﹤0.01% 2571
2017
Q4
$223K Sell
5,158
-1,619
-24% -$72.8K ﹤0.01% 2586
2017
Q3
$315K Buy
6,777
+110
+2% +$5.27K ﹤0.01% 2534
2017
Q2
$330K Buy
6,667
+466
+8% +$24.4K ﹤0.01% 2509
2017
Q1
$340K Buy
6,201
+412
+7% +$21.8K ﹤0.01% 2445
2016
Q4
$322K Buy
5,789
+439
+8% +$21.1K ﹤0.01% 2455
2016
Q3
$244K Buy
5,350
+220
+4% +$8.84K ﹤0.01% 2584
2016
Q2
$205K Buy
+5,130
New +$188K ﹤0.01% 2729
2016
Q1
Sell
-4,804
Closed -$206K 3002
2015
Q4
$206K Buy
+4,804
New +$241K ﹤0.01% 2784

Other funds holding BSTC

RhumbLine Advisers's BSTC Position: Q4 2020 in Review

RhumbLine Advisers sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 7,117 shares — an estimated $376K sold.

RhumbLine Advisers first reported a position in BSTC in Q4 2015 and held it in 19 quarters. The position peaked at $503K in Q2 2020. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.

  • RhumbLine Advisers reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
  • RhumbLine Advisers sold 7,117 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $376K.
  • RhumbLine Advisers first reported a position in BioSpecifics Technologies Corp. in Q4 2015 and held it in 19 quarters.
  • RhumbLine Advisers's BioSpecifics Technologies Corp. position peaked at $503K in Q2 2020.
  • 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.

Based on RhumbLine Advisers's 13F filing for Q4 2020, filed 10 Feb 2021.